SynthesisEuropean journal of clinical pharmacology2026
Cost-effectiveness of sofosbuvir- ledipasvir for Hepatitis C treatment: a systematic review.
Synthesis in European journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHepatitis C virus (HCV) infection remains a major cause of liver-related morbidity and mortality, affecting about 50 million people worldwide. Given its global priority, high treatment costs, and equity concerns, evaluating the cost-effectiveness of HCV therapies is crucial for informing policy and resource allocation. This systematic review synthesizes the cost-effectiveness of sofosbuvir/ledipasvir (SOF/LDV) compared with alternative regimens in patients with HCV.
methodsA systematic search was conducted across major databases and additional sources following PRISMA 2020 guidelines. Eligible studies were full economic evaluations comparing SOF/LDV with other treatments. Methodological quality was assessed using the Quality of Health Economic Studies (QHES) checklist. Incremental cost-effectiveness ratios (ICERs) were adjusted to 2024 U.S. dollars, and findings were synthesized qualitatively.
resultsOf 864 retrieved records, 15 met inclusion criteria, with a mean QHES score of 88.6, reflecting high methodological quality. Seven studies identified SOF/LDV as cost-effective or dominant across various healthcare systems, perspectives, and time horizons, particularly for genotype 1 and early stages liver disease. However, results varied by genotype, fibrosis stage, comparator, and national healthcare settings. Sensitivity analyses showed that ICERs were mainly influenced by patient age, utility values, treatment costs, dosage, treatment duration, discount rate, sustained virologic response (SVR) rate, fibrosis progression probabilities, and mortality rates.
conclusionSOF-based regimens play a pivotal role in HCV management. However, contextual factors—such as healthcare infrastructure, willingness-to-pay thresholds, and model assumptions— significantly influence cost-effectiveness. Future research should address geographic inequities, incorporate societal perspectives, reduce methodological heterogeneity, and integrate real-world data to enhance generalizability.
Indexed as
Identifiers
41942791What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.